Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Dana-Farber Cancer Institute, Inc. v. Bristol-Myers Squibb Co. et al
Case Number:
1:19-cv-11380
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
February 19, 2026
She Has A Point: Dechert's Kassie Helm
Kassie Helm, co-chair of Dechert LLP's global intellectual property group and head of its IP litigation group, is "unquestionably one of the leading lights of her generation," according to Morrison Foerster LLP partner Daralyn Durie, who praised Helm for her work as opposing counsel in a new series celebrating women litigators.
-
April 06, 2023
Bristol-Myers, Dana-Farber Settle Cancer IP Dispute
Bristol-Myers Squibb Co. and the Dana-Farber Cancer Institute have resolved a dispute in Massachusetts federal court over licensing revenue for six groundbreaking immunology patents, according to a Thursday court filing.
-
January 25, 2023
Bristol-Myers Gets Pushback On Early Win Bid Over Cancer IP
Bristol-Myers Squibb Co. faced headwinds in Boston federal court Wednesday in arguing for a pretrial win in a lawsuit claiming it robbed Dana-Farber Cancer Institute of licensing revenue from groundbreaking immunology patents the research center now co-owns.
-
August 01, 2022
Bristol-Myers Says Its Former Lawyer Can't Testify In IP Battle
Bristol-Myers Squibb Co. told a federal judge that Dana-Farber Cancer Institute should not be allowed to bring in a former BMS patent attorney from McDonnell Boehnen Hulbert & Berghoff LLP to testify against his onetime client as part of an ongoing dispute over immunology patents.
-
August 16, 2021
Judge Lets Dana-Farber Advance Cancer Drug IP Suit
A Massachusetts federal judge has found that the Dana-Farber Cancer Institute made a plausible argument asserting that it is entitled to damages after Bristol-Myers Squibb left the research center's name off immunology patents.
-
April 26, 2021
Pfizer 'Bonus' Irks Judge In Bristol-Myers Cancer IP Dispute
A Massachusetts federal judge on Monday grilled Bristol-Myers Squibb Co. and Dana-Farber Cancer Institute over "troubling" settlement terms related to their prior high-profile patent ownership case that appeared to offer a bonus to intervenor Pfizer Inc. if the Boston nonprofit cancer hospital lost the case.
-
June 24, 2019
Cancer Center Claims Drug Cos. 'Robbed' It Of IP Revenue
Boston-based Dana-Farber Cancer Institute says it should get a cut of more than $1.6 billion in licensing revenue Bristol-Myers Squibb Co. and Ono Pharmaceutical Co. Ltd. have raked in from immunology patents the institute says it co-owns, according to a new lawsuit.